Utility of a 40-minute LH level after depot leuprolide for diagnosis and treatment monitoring in girls with CPP
Open Access
- 26 May 2026
- journal article
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (9) , 2375-2383
Abstract
Purpose: Gonadotropin-releasing-hormone (GnRH) stimulation test is used for assessment of gonadotropic activation in patients with central precocious puberty (CPP). However, it is invasive and GnRH preparation is not available in all countries. Depot-leuprolide acetate (dLA), used for the treatment of CPP, stimulates gonadotropins briefly before suppressing them. This study aimed to evaluate the utility of luteinizing hormone (LH) level measured 40-minutes after dLA injection for assessing gonadotropic activation compared to GnRH stimulation test. Methods: In this prospective study, girls with idiopathic CPP were randomized to receive dLA 3.75 mg/4 weeks IM, 11.25 mg/12 weeks SC or 11.25 mg/12 weeks IM. A standard GnRH test was performed before (baseline) and after 6 months of treatment. Forty minutes after the first dLA injection, LH and follicle-stimulating hormone (FSH) levels were measured, and the same measurements were repeated after 6 months of treatment. Results: The study recruited 132 girls. Peak LH on the GnRH test did not differ from the 40-minute-post-dLA LH levels [11.0(6.8–17.1) vs. 9.4(5.8–16.6); p = 0.06]. There were no significant differences between the treatment groups. Using the GnRH test peak of LH ≥ 5 IU/L as the gold-standard, ROC analysis identified the optimal cut-off of post-dLA injection LH ≥ 5.4 IU/L on initial measurement (sensitivity = 86%, specificity = 90% and AUC = 0.91). At 6 months, peak LH levels in treatment groups were similarly suppressed (2.1 ± 1.6, 2.5 ± 1.8, 2.2 ± 0.9; p = 0.2011). Furthermore, post- dLA LH cut-off of < 3.07 IU/L yielded an AUC = 0.83, sensitivity = 80.8% and specificity = 75.5%. Conclusion: The 40-minute post-dLA LH provided clinically useful information concerning gonadotropic activity for both diagnosis and treatment monitoring and may provide a practical and clinically informative alternative in selected settings, particularly when standard GnRH testing is not readily available.Keywords
Funding Information
- Marmara Üniversitesi
This publication has 31 references indexed in Scilit:
- A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious PubertyAdvances in Therapy, 2024
- Diagnostic Value of Single LH and LH/FSH Ratio at 60-minute after GnRHa Stimulation Test for Central Precocious PubertyIndian Journal of Pediatrics, 2024
- Gonadotropin and Estradiol Levels after Leuprolide Stimulation Tests in Brazilian Girls with Precocious PubertyJournal of Pediatric and Adolescent Gynecology, 2015
- Central Precocious Puberty: Update on Diagnosis and TreatmentPediatric Drugs, 2015
- Central Precocious Puberty: Treatment with Triptorelin 11.25 mgThe Scientific World Journal, 2012
- ORIGINAL ARTICLE: Leuprolide stimulation testing for the evaluation of early female sexual maturationClinical Endocrinology, 2010
- Growth references for Turkish children aged 6 to 18 yearsActa Paediatrica, 2006
- Body mass index references for Turkish childrenActa Paediatrica, 2006
- Pelvic ultrasonography: Early differentiation between isolated premature thelarche and central precocious pubertyEuropean Journal of Pediatrics, 1995
- RADIOGRAPHIC ATLAS OF SKELETAL DEVELOPMENT OF THE HAND AND WRISTThe American Journal of the Medical Sciences, 1959